Advertisement

Topics

Latest "Global Polyalkene Glycol Based Lubricants Market Research Report" News Stories - Page: 4

15:28 EDT 23rd March 2019 | BioPortfolio

Here are the most relevant search results for "Global Polyalkene Glycol Based Lubricants Market Research Report" found in our extensive news archives from over 250 global news sources.

More Information about Global Polyalkene Glycol Based Lubricants Market Research Report on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Global Polyalkene Glycol Based Lubricants Market Research Report for you to read. Along with our medical data and news we also list Global Polyalkene Glycol Based Lubricants Market Research Report Clinical Trials, which are updated daily. BioPortfolio also has a large database of Global Polyalkene Glycol Based Lubricants Market Research Report Companies for you to search.

Showing "Global Polyalkene Glycol Based Lubricants Market Research Report" News Articles 76–100 of 58,000+

Friday 22nd March 2019

LegoChem and Takeda Partner for the Development of Antibody-Drug Conjugates in Immuno-Oncology

DAEJEON, South Korea–(BUSINESS WIRE)–LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080) announced today that it has entered a research collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the development of antibody-drug conjugates in immuno-oncology. Takeda gains certain rights to LCB’s antibody-drug conjugate (ADC) technology, C...


Human medicines European public assessment report (EPAR): Intrarosa, prasterone, Menopause, Date of authorisation: 08/01/2018, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Intrarosa, prasterone, Menopause, Date of authorisation: 08/01/2018, Revision: 2, Status: Authorised

FDA Warns About the Risks Associated with the Investigational Use of Venclexta in Multiple Myeloma

[3/21/2019] The U.S. Food and Drug Administration is alerting health care professionals, oncology clinical investigators and patients about the risks associated with the investigational use of Venclexta (venetoclax) for the treatment of patients with multiple myeloma based on data from a clinical trial. Venclexta is not approved for the treatment of multiple myeloma. FDA reviewed data …


OncLive® Presents State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma

The summit will feature expert faculty from Memorial Sloan Kettering Cancer Center OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need to provide the best patient care, will host its latest State of the Science Summit™ on ovarian cancer and soft tiss...

The AMR Centre secures £2.3m funding boost

The AMR Centre, a body with public and private investors leading the UK’s response to the global health threat posed by antimicrobial resistance, has received a significant funding package to support the expansion of its pipeline of new drugs to treat drug-resistant infections.

Gottlieb: Valsartan API Crisis Spurs Drug GMP Revision

FDA commissioner discloses effort underway to tighten oversight of changes to active pharmaceutical ingredient manufacturing processes by rewriting parts of...   

Long-term use of inexpensive weight-loss drug may be safe and effective

An inexpensive weight-loss drug approved 60 years ago for only short-term use also may be safe and effective for longer-term treatment, according to a study conducted by researchers at Wake Forest Baptist Health and the Patient Outcomes Research to Advance Learning network.

Cannabis Report: Curaleaf beliefert US-Apotheken mit CBD-Produkten

(shareribs.com) New York 22.03.2019 - Die US-Apothekenkette CVS wird künftig in 800 Filialen CBD-Produkte verkaufen. Diese werden von Curaleaf geliefert, welche am Mittwoch Zahlen vorlegte und die ...

Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Neuroblastoma, Date of authorisation: 08/05/2017, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Neuroblastoma, Date of authorisation: 08/05/2017, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Zeffix, lamivudine, Hepatitis B, Chronic, Date of authorisation: 28/07/1999, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Zeffix, lamivudine, Hepatitis B, Chronic, Date of authorisation: 28/07/1999, Revision: 23, Status: Authorised

Coral Reefs Near Equator Less Affected by Ocean Warming

NewsResearch based on analysis of field observations from 20-year global coral survey.Contributed Author: 

AAAAI Installs New President, Dr. David Lang, at 2019 Annual Meeting

David M. Lang, MD, FAAAAI, is Chairman of the Department of Allergy and Clinical Immunology, Co-Director of the Asthma Center, and Director of the Allergy/Immunology Fellowship Training Program in the Respiratory Institute at the Cleveland Clinic. MILWAUKEE (PRWEB) March 22, 2019 The American Academy of Allergy, Asthma & Immunology (AAAAI) is pleased to introduce its 2019-2020 President, Davi...

UnitedHealthcare Launches National Vision Laboratory Network Relationship with Essilor Labs

UnitedHealthcare, a UnitedHealth Group (NYSE: UNH) company, has launched a national vision laboratory network to better serve eye care professionals and meet the needs of more than 19 million vision plan participants. The laboratory network has launched in collaboration with Essilor, which operates the largest optical lab network in the country. T...

USAWorldMeds Names Neurologist & Addiction Medicine Specialist Dr. Russell Surasky as Expert Speaker for New Ground-Breaking Medication Lucemyra

Lucemyra is the First FDA Approved Medicine to Treat Opioid Withdrawal Syndrome (OWS). GREAT NECK. N.Y. (PRWEB) March 22, 2019 “Not a day goes by when we don’t learn more about the devastation caused by opioid addiction. Every day in the United States approximately 4,000 individuals start using opiates for non-medical purposes. We are now up to about 130 opioid overdoses per day,” says Neur...

Sharp Transitions Named $100k Winner of 2019 Hearst Health Prize

Hearst Health, in partnership with the Jefferson College of Population Health has namedSharp Transitions as the winner of the 2019 Hearst Health Prize for its home-based palliative care program for patients with advanced and progressive chronic illness who are not ready for hospice care. The $100k annual award was given at the Population Health Colloquium ... Read More

4D Printing Could Lead to Small, Implantable Medical Devices

Engineers at Rutgers University-New Brunswick report the creation of flexible, lightweight materials with 4D printing that could lead to small implantable biomedical devices, among other applications. Their study (“4D Printing Reconfigurable, Deployable and Mechanically Tunable Metamaterials”) appears in Materials Horizons. “Exotic properties of mechanical metamaterials emerge from the topol...

Merck Portfolio: Halftime Report

#news #biotech Conatus and Novartis suffer another midphase NASH flop

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Conatus and Novartis suffer another midphase NASH flop .Conatus Pharmaceuticals’ emricasan has failed another midphase clinical trial. The latest setback saw the Novartis-partnered liver disease drug fail to … Continue reading →

#news #biotech J&J dumps Alios RSV drug, wiping remaining $900M off value

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: J&J dumps Alios RSV drug, wiping remaining $900M off value .Johnson & Johnson has abandoned development of anti-RSV drug AL-8176, wiping another $900 million off the value of … Continue reading →

Biofrontera Aktie: Starkes Aufwärtspotenzial

Die Analysten von SMC Research erwarten für die Biofrontera Aktie weiterhin hohe Kursgewinne. Während der Aktienkurs des Unternehmens aus Leverkusen am Freitag bei 5,47 Euro auf einem unveränderten...

UK MHRA Clarifies No Deal Brexit Plans For PIPs

The Medicines and Healthcare products Regulatory Agency explains how it would deal with pediatric investigation plans if the ...

CCG report shows increase in emergency readmissions

NHS Digital has published emergency readmissions statistics for first time in five years.

uBiome Awards Grant to Nnamdi Azikiwe University to Study the Influence of Probiotics on the Urinary Tract Microbiome

Researchers will use the grant to investigate the effect of probiotics on the urinary tract microbiome. SAN FRANCISCO (PRWEB) March 22, 2019 uBiome has awarded microbiome research support in study design, planning, sample collection, and analysis to a team of researchers at Nnamdi Azikiwe University in Anambra State, Nigeria led by Dr. Kingsley C. Anukam, PhD, and supported by Dr. Nneka R. Agboko...

SoFi and Delos Partner to Bring Delos’ Home Wellness Solutions to Homeowners

The partnership will help drive accessibility of Delos’ health and wellness technology to homes across the U.S. Wellness real estate and technology company, Delos™, is collaborating with online personal finance company, SoFi, to ensure homeowners will have an accessible financing path to implement Delos’ DARWIN Home Wellness Intelligence Network,...

AI drug R&D firm Exscientia expands into Japan

AI drug R&D firm Exscientia has announced it has expanded into Japan, after clinching a major research deal with Celgene. Based in Oxford, UK, Exscientia said it has established a subsidiary, Exscientia K.K. which is to spearhead its pharmaceu...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks